Group One Trading’s Dianthus Therapeutics DNTH Stock Holding History

Group One Trading’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$126K	Buy	1,431 +1,342	+1,508%	+$139K	﹤0.01%	4532
2026 Q2	$8.68K	Sell	89 -3,364	-97%	-$294K	﹤0.01%	6480
2026 Q1	$290K	Buy	3,453 +2,621	+315%	+$152K	﹤0.01%	3823
2025 Q4	$34.3K	Buy	+832	New	+$32.3K	﹤0.01%	5907
2020 Q4	–	Sell	-50	Closed	-$5.67K	–	6590
2020 Q3	$5K	Buy	50 +19	+61%	+$2.25K	﹤0.01%	5631
2020 Q2	$4K	Buy	31 +18	+138%	+$2.54K	﹤0.01%	5414
2020 Q1	$1K	Sell	13 -12	-48%	-$2.22K	﹤0.01%	5066
2019 Q4	$6K	Buy	+25	New	+$4.67K	﹤0.01%	4711

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Group One Trading's DNTH Position: Q3 2026 in Review

Group One Trading increased its Dianthus Therapeutics (DNTH) stake by 1,508% in Q3 2026, buying an estimated $139K and bringing the position to 1,431 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #4532.

Group One Trading first reported a position in DNTH in Q4 2019 and has held it in 8 quarters since. The position peaked at $290K in Q1 2026. 109 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Group One Trading held 1,431 shares of Dianthus Therapeutics worth $126K as of Q3 2026.
Group One Trading bought 1,342 Dianthus Therapeutics shares in Q3 2026, an estimated $139K.
Dianthus Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #4532 holding.
Group One Trading first reported a position in Dianthus Therapeutics in Q4 2019 and has held it in 8 quarters since.
Group One Trading's Dianthus Therapeutics position peaked at $290K in Q1 2026.
109 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.